Amgen Inc. (BCBA:AMGN)

Market Cap	288.32T +86.0%
Revenue (ttm)	53.34T +10.0%
Net Income	11.19T +88.5%
EPS	20,653.42 +88.2%
Shares Out	n/a
PE Ratio	25.76
Forward PE	16.73
Dividend	253.23 (1.40%)
Ex-Dividend Date	Nov 21, 2025

Volume	1,139
Average Volume	2,277
Open	18,300
Previous Close	18,520
Day's Range	17,930 - 18,370
52-Week Range	10,050 - 19,260
Beta	0.45
RSI	64.30
Earnings Date	Feb 3, 2026

About Amgen

Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company’s principal products include Enbrel for the treatment of rheumatoid arthritis, plaque psoriasis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet’s disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascul...

• Industry: Drug Manufacturers - General
• Sector: Healthcare
• Founded: 1980
• Employees: 28,000
• Stock Exchange: Buenos Aires Stock Exchange
• Ticker Symbol: AMGN

Financial Performance

In 2025, Amgen's revenue was $36.75 billion, an increase of 9.95% compared to the previous year's $33.42 billion. Earnings were $7.71 billion, an increase of 88.53%.

Financial numbers in USD